Hong Kong stock concept tracking | National Medical Insurance Administration sets separate items for brain-machine interface medical service prices Brain-machine interface enters a period of rapid development (with concept stocks)

Recently, the National Healthcare Security Administration compiled and issued the "Neurological Medical Service Price Project Approval Guidelines," referring to the 2023 version of the technical specifications for medical service projects. They integrated the current neurological price projects into 82 items, added 24 items, and expanded 8 items. The next step will be to guide each province's healthcare security administration to refer to this, and to coordinate and implement it effectively in practice. They will establish a unified pricing baseline for the entire province, and pricing levels will be determined by comparing to the provincial baseline by the coordinating region with pricing management authority. The National Healthcare Security Administration also released the "Neurological Medical Service Price Project Approval Guidelines," which specifically included a separate item for new brain-machine interface technology. They set prices for invasive brain-machine interface implantation fees, extraction fees, non-invasive brain-machine interface adaptation fees, and other price items. This means that once brain-machine interface technology matures, the fee path for rapid clinical application is already laid out. According to the National Medical Products Administration Medical Device Technical Review Inspection Grand Bay Area Center, a team led by the director Liu Bin recently conducted a survey at the South China University of Technology and Pazhou Lab to further investigate the situation of advanced brain-machine interface technology conversion in the region and to increase support for research and development innovation. The team visited the real-time decoding upper and lower limb comprehensive rehabilitation training system based on brain-machine interface and the multimodal brain-machine fusion wheelchair for patients with movement disorders. They also listened to introductions of brain-machine interface technology-related achievements and the difficulties encountered during the registration and declaration process by the South China University of Technology and Pazhou Lab. The team engaged in on-site exchanges on the classification of registered products, registration pathways, safety and efficacy evaluations, and provided corresponding solutions and suggestions. Huaan released a research report stating that the brain-machine interface (BCI) industry has entered a period of high-speed development. It is predicted that the global market size will reach $1.98 billion in 2023, and is expected to surpass $6 billion in 2028, with a compound annual growth rate of 25.22% over five years. China has overtaken with non-invasive technology, pioneering the "dual-loop" brain-machine interaction system, breaking through traditional control restrictions, and occupying a leading position globally. Medical health is currently the most mature track for brain-machine interfaces, and the technology is also permeating into the education, entertainment, military, and other fields. The core challenges faced by China's brain-machine interface industry include: 1) limitations in basic disciplines; 2) technological bottlenecks and deficiencies in the industrial chain; 3) ethical and regulatory risks. A Western research report points out that neuroscience and neuromorphic research is one of the seven key frontiers in science and technology for the "14th Five-Year Plan". Brain-machine interface technology is one of the core key technologies with promising application prospects. It is suggested to focus on overseas targets in the 0-1 stage, as well as domestic mapping. Concept stocks related to brain-machine interfaces listed on the Hong Kong Stock Exchange: - NANJING PANDA (00553): Nanjing Panda Electronics previously stated on the investor interaction platform that the company is involved in provincial key research and development programs related to brain-machine interfaces, and is currently in the research and development stage. - HEARTCARE-B (06609): On June 25, 2023, China's domestically developed first instance of an invasive brain-machine interface successfully completed animal testing in Beijing. This invasive brain-machine interface was jointly developed by Professor Duan Feng's research team from the School of Artificial Intelligence at Nankai University and Xinwei Medical.